Antioxidants and cataracts
This article was originally published in The Tan Sheet
Executive Summary
Roche European American Cataract Trial (REACT) finds three-year daily use of antioxidant cocktail produces "small deceleration in progression of [age-related cataract]," Leo Chylack, MD, Brigham & Women's Hospital, Boston, et al., report in November Ophthalmic Epidemiology. Partly funded by Hoffmann-La Roche and Roche Vitamins, trial included 297 American and British early ARC patients randomly dosed with placebo or combinations of 18 mg beta carotene, 750 mg vitamin C, 600 mg vitamin E. Cataract severity was documented using serial digital retroillumination imagery, progression was measured as "increase % pixels opaque." Findings follow recent research showing antioxidants and zinc reduce risk of developing advanced age-related macular degeneration (1"The Tan Sheet" Oct. 15, p. 3)...
You may also be interested in...
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study
Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.